| Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model A Bargiela, E Cerro-Herreros, JM Fernandez-Costa, JJ Vilchez, B Llamusi, ... Disease models & mechanisms 8 (7), 679-690, 2015 | 89 | 2015 |
| miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models E Cerro-Herreros, M Sabater-Arcis, JM Fernandez-Costa, N Moreno, ... Nature Communications 9 (1), 2482, 2018 | 75 | 2018 |
| rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences C Sellier, E Cerro-Herreros, M Blatter, F Freyermuth, A Gaucherot, ... Nature communications 9 (1), 2009, 2018 | 65 | 2018 |
| RNA-mediated therapies in myotonic dystrophy SJ Overby, E Cerro-Herreros, B Llamusi, R Artero Drug discovery today 23 (12), 2013-2022, 2018 | 48 | 2018 |
| Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila E Cerro-Herreros, JM Fernandez-Costa, M Sabater-Arcis, B Llamusi, ... Scientific reports 6 (1), 36230, 2016 | 48 | 2016 |
| Therapeutic potential of AntagomiR-23b for treating myotonic dystrophy E Cerro-Herreros, I González-Martínez, N Moreno-Cervera, S Overby, ... Molecular Therapy-Nucleic Acids 21, 837-849, 2020 | 37 | 2020 |
| Bioengineered in vitro 3D model of myotonic dystrophy type 1 human skeletal muscle X Fernandez-Garibay, MA Ortega, E Cerro-Herreros, J Comelles, ... Biofabrication 13 (3), 035035, 2021 | 26 | 2021 |
| Two Enhancers Control Transcription of Drosophila muscleblind in the Embryonic Somatic Musculature and in the Central Nervous System A Bargiela, B Llamusi, E Cerro-Herreros, R Artero PloS one 9 (3), e93125, 2014 | 19 | 2014 |
| Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes E Cerro-Herreros, M Chakraborty, M Pérez-Alonso, R Artero, B Llamusí Scientific Reports 7 (1), 2843, 2017 | 17 | 2017 |
| Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model SJ Overby, E Cerro-Herreros, I González-Martínez, MA Varela, ... Molecular Therapy-Nucleic Acids 27, 1146-1155, 2022 | 14 | 2022 |
| Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy E Cerro-Herreros, I González-Martínez, N Moreno, J Espinosa-Espinosa, ... Molecular Therapy-Nucleic Acids 26, 174-191, 2021 | 14 | 2021 |
| BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice SJ Overby, E Cerro-Herreros, J Espinosa-Espinosa, I González-Martínez, ... Pharmaceutics 15 (4), 1118, 2023 | 2 | 2023 |
| Rapid determination of MBNL1 protein levels by quantitative dot blot for the evaluation of antisense oligonucleotides in myotonic dystrophy myoblasts N Moreno, I González-Martínez, R Artero, E Cerro-Herreros Antisense RNA Design, Delivery, and Analysis, 207-215, 2022 | 2 | 2022 |
| Oligonucleotides conjugated to oleic acid and uses thereof RA ALLEPUZ, NM CERVERA, IG MARTÍNEZ, EC HERREROS, ... US Patent App. 18/322,487, 2023 | | 2023 |
| Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression I González-Martínez, E Cerro-Herreros, N Moreno, A García-Rey, ... Molecular Therapy-Nucleic Acids 34, 2023 | | 2023 |
| Modulation of micrornas against myotonic dystrophy type 1 and antagonists of micrornas therefor RDA ALLEPUZ, MBL TROISI, EC HERREROS, JMF COSTA, V Aishwarya, ... US Patent App. 17/525,672, 2022 | | 2022 |
| Bioengineered in vitro 3D model of myotonic dystrophy type 1 human skeletal muscle X Fernández-Garibay, MA Ortega, E Cerro-Herreros, J Comelles, ... TISSUE ENGINEERING PART A 28, S591-S591, 2022 | | 2022 |
| Modulation of micrornas against myotonic dystrophy type 1 and antagonists of micrornas therefor RDA ALLEPUZ, MB LlamusíTroisi, EC HERREROS, JMF COSTA, ... US Patent 11,202,794, 2021 | | 2021 |
| Muscleblind-like 1 regulates epithelial to mesenchymal transition markers in triple-negative breast cancer AA Artigues, E Tormo, E Cerro-Herreros, M Sabater, I Garrido-Cano, ... Annals of Oncology 29, vi32, 2018 | | 2018 |
| Utilización de micrornas como dianas terapéuticas en distrofia miotónica EC Herreros Universitat de València, 2018 | | 2018 |
